Biotech

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BELLUS Health Inc. from September 5, 2019, through July 5, 2020 . The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934. If ...

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BELLUS Health Inc. ("BELLUS " or the "Company") (NASDAQ: BLU) from September 5, 2019, through July 5, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased BELLUS securities, and/or would like to discuss your legal rights and options please visit Bellus Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors that BLU-5937 had a much higher risk of failing to demonstrate efficacy for chronic cough. Accordingly, despite Merck's successful Phase 2 study, BLU-5937 had a high risk of failing its Phase 2 study.

Before markets opened on July 6, 2020, Defendants revealed the truth about BLU-5937's efficacy. They announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed. The Phase 2 trial showed a "clinically meaningful and highly statistically significant effect only on a subset of patients who had high cough counts (around 32 per day), so the Company was planning a Phase 2b trial focused on those patients.

On this news, indicating that BELLUS had fallen even further behind Merck in developing an FDA-approved treatment for refractory chronic cough, the Company's stock price plummeted over 75% to close at $2.97 on July 8, 2020 on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased BELLUS securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/bellushealthinc-blu-shareholder-class-action-lawsuit-stock-fraud-380/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

U.S. FDA Approves RINVOQ® to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

ABBVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. 1 RINVOQ 15 mg once daily can be initiated in adults and children 12 years of age and older weighing at least 40 kg. 1 In these children and adults less than 65 years of age who do not achieve an adequate response, the dose may be increased to 30 mg once daily. 1

"Early in my career as an allergist, I saw how relentless the itch and rash could be for my patients with moderate to severe atopic dermatitis yet had limited options to offer those whose disease could not be adequately controlled with systemic therapy," said Thomas Hudson , M.D., senior vice president, research and development, chief scientific officer, AbbVie. "This additional approval for RINVOQ provides a once-daily oral option that can significantly improve the debilitating itch and skin symptoms of atopic dermatitis. It's also a proud moment for AbbVie as we continue our efforts to improve care in this disease state and other chronic, immune-mediated conditions."

Keep reading... Show less
Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the second tranche of its previously announced non-brokered private placement financing (the "Financing") (see news release dated November 23, 2021 and December 23, 2021) by issuing 37,348,532 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $1,120,455.96 (the "Second Tranche"). In total, the Company has issued 109,032,378 Units for gross proceeds of $3,270,971.34 under the entire private placement financing. The Financing has been oversubscribed by $270,971.34

Each Unit in the Second Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

Keep reading... Show less

TEZSPIRE NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

- Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. 1

"Severe asthma has historically been a complex disease for patients to manage and for physicians to treat," said Murdo Gordon , executive vice president of Global Commercial Operations at Amgen. "About 60 percent of people have multiple drivers of disease and may not respond well to existing treatments. TEZSPIRE was approved for a broad population of people living with severe asthma, and we look forward to getting this important medicine into the hands of millions of patients who have had an unmet medical need."

Keep reading... Show less
Komo Plant Based Foods to Launch in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods to Launch in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce all 7 Whole Foods Market retail locations in Western Canada will begin carrying Komo Plant Based Comfort Foods. Komo products are planogrammed to be on the shelves in all 7 stores in early 2022. Whole Foods has expanded to 6 stores within key neighbourhoods in the greater Vancouver area and most recently opened a flagship store in the capital city of Victoria on southern Vancouver Island

Whole Foods Market, Inc. is an American multinational supermarketchain headquartered in Austin, Texas, which sells organic foods and products free from hydrogenated fats and artificial colors, flavors, and preservatives. Whole Foods seeks out the finest natural and organic foods available, maintains the strictest quality standards in the industry, and has an unshakeable commitment to sustainable agriculture. Whole Foods has more than 500 retail and non-retail locations in the US, Canada and the United Kingdom. It has 14 retail locations in Canada, of which 7 are in British Columbia, and 7 are in Ontario. In 2017, Amazon purchased Whole Foods Market for USD$13.7 Billion.

Keep reading... Show less

Top Canadian Biotech Stocks

Click here to read the previous top Canadian biotech stocks article.

Although it’s not as large as the US biotech industry, the Canadian biotech market is still making a name for itself on the global investment stage in terms of size and opportunities.

In recent years, the biotech sector worldwide has become a “real industry” that has brought “spectacular” returns for mid-cap companies, according to Jessica Chutter, managing director and chairman of biotechnology investment banking with Morgan Stanley (NYSE:MS).

Much of the growth in biotech is attributable to technology advancements in drug research and development, said Chutter, who was speaking at a virtual event hosted by the Globe and Mail.

Keep reading... Show less
Solarvest To Sell on China's E-Commerce Application Redbook

Solarvest To Sell on China's E-Commerce Application Redbook

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest ( TSXV:SVS ) is pleased to announce that the Eversea TM "branded" account has been launched on the Chinese e-commerce platform application Redbook

Keep reading... Show less

Latest Press Releases

Related News

×